LONG-TERM USE OF DENOSUMAB IN GIANT CELL TUMORS AND VERTEBRAL ANEURYSMAL BONE CYSTS

ABSTRACT Introduction: Denosumab is a human monoclonal antibody that binds to the receptor activator of nuclear factor kB (RANKL), it used in treatment Osteoporosis. The Giant Cell Tumor (GCT) and Aneurysmal Bone Cyst (ABC) use same RANKL, for this reason drug began be its treatment. There consensus on use, dose-time 12-month duration GCT. Not so ABC. In unresectable, disabling or recurrent tumors, could life. adverse events habitual are known, but not known if these increase with time. objective present work identify possible more than 12 months. Material Method: Series cases diagnosis GCT ABC spine, treated Adverse are: arthralgia, fatigue, spinal pain, pain extremities, headache, hypokalaemia, hypocalcemia, osteonecrosis jaw, malignant transformation, pathological fractures. Results: Eight patients, 6 TCG 2 ABC, mean age at 25,6 years; presenting 4.18 years (range 1.7 - 8.7). Of operated 4 had recurrence (2 36 months after surgery). One patient suspend due necrosis another both returned when stabilized. Conclusions: A minor event (hypocalcemia) major (jaw bone necrosis) were observed. Level Evidence IV; Original.